BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35568767)

  • 1. The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein.
    Pianigiani G; Rocchio F; Peruzzi S; Andresen V; Bigerna B; Sorcini D; Capurro M; Gjertsen BT; Sportoletti P; Di Ianni M; Martelli MP; Brunetti L; Falini B
    Leukemia; 2022 Jul; 36(7):1931-1934. PubMed ID: 35568767
    [No Abstract]   [Full Text] [Related]  

  • 2. CD34+ cells from AML with mutated NPM1 harbor cytoplasmic mutated nucleophosmin and generate leukemia in immunocompromised mice.
    Martelli MP; Pettirossi V; Thiede C; Bonifacio E; Mezzasoma F; Cecchini D; Pacini R; Tabarrini A; Ciurnelli R; Gionfriddo I; Manes N; Rossi R; Giunchi L; Oelschlägel U; Brunetti L; Gemei M; Delia M; Specchia G; Liso A; Di Ianni M; Di Raimondo F; Falzetti F; Del Vecchio L; Martelli MF; Falini B
    Blood; 2010 Nov; 116(19):3907-22. PubMed ID: 20634376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
    Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
    Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia.
    Dang H; Chen Y; Kamel-Reid S; Brandwein J; Chang H
    Hum Pathol; 2013 Oct; 44(10):2038-46. PubMed ID: 23701943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.
    Haferlach C; Mecucci C; Schnittger S; Kohlmann A; Mancini M; Cuneo A; Testoni N; Rege-Cambrin G; Santucci A; Vignetti M; Fazi P; Martelli MP; Haferlach T; Falini B
    Blood; 2009 Oct; 114(14):3024-32. PubMed ID: 19429869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity?
    Falini B; Martelli MP; Bolli N; Sportoletti P; Liso A; Tiacci E; Haferlach T
    Blood; 2011 Jan; 117(4):1109-20. PubMed ID: 21030560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered nucleophosmin transport in acute myeloid leukaemia with mutated NPM1: molecular basis and clinical implications.
    Falini B; Bolli N; Liso A; Martelli MP; Mannucci R; Pileri S; Nicoletti I
    Leukemia; 2009 Oct; 23(10):1731-43. PubMed ID: 19516275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.
    Konoplev S; Huang X; Drabkin HA; Koeppen H; Jones D; Kantarjian HM; Garcia-Manero G; Chen W; Medeiros LJ; Bueso-Ramos CE
    Cancer; 2009 Oct; 115(20):4737-44. PubMed ID: 19637342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoplasmic Expression of TP53INP2 Modulated by Demethylase FTO and Mutant NPM1 Promotes Autophagy in Leukemia Cells.
    Huang J; Sun M; Tao Y; Ren J; Peng M; Jing Y; Xiao Q; Yang J; Lin C; Lei L; Yang Z; Zhang L
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy?
    Falini B; Gionfriddo I; Cecchetti F; Ballanti S; Pettirossi V; Martelli MP
    Blood Rev; 2011 Nov; 25(6):247-54. PubMed ID: 21724308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imidazoquinoxaline derivative EAPB0503: A promising drug targeting mutant nucleophosmin 1 in acute myeloid leukemia.
    Nabbouh AI; Hleihel RS; Saliba JL; Karam MM; Hamie MH; Wu HJM; Berthier CP; Tawil NM; Bonnet PA; Deleuze-Masquefa C; El Hajj HA
    Cancer; 2017 May; 123(9):1662-1673. PubMed ID: 28055106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When the good go bad: Mutant NPM1 in acute myeloid leukemia.
    Kunchala P; Kuravi S; Jensen R; McGuirk J; Balusu R
    Blood Rev; 2018 May; 32(3):167-183. PubMed ID: 29157973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant NPM1 Maintains the Leukemic State through HOX Expression.
    Brunetti L; Gundry MC; Sorcini D; Guzman AG; Huang YH; Ramabadran R; Gionfriddo I; Mezzasoma F; Milano F; Nabet B; Buckley DL; Kornblau SM; Lin CY; Sportoletti P; Martelli MP; Falini B; Goodell MA
    Cancer Cell; 2018 Sep; 34(3):499-512.e9. PubMed ID: 30205049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies FLT3-Mutated Clones in Acute Myeloid Leukemia.
    Angelini DF; Ottone T; Guerrera G; Lavorgna S; Cittadini M; Buccisano F; De Bardi M; Gargano F; Maurillo L; Divona M; Noguera NI; Consalvo MI; Borsellino G; Bernardi G; Amadori S; Venditti A; Battistini L; Lo-Coco F
    Clin Cancer Res; 2015 Sep; 21(17):3977-85. PubMed ID: 25957287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells.
    Martelli MP; Gionfriddo I; Mezzasoma F; Milano F; Pierangeli S; Mulas F; Pacini R; Tabarrini A; Pettirossi V; Rossi R; Vetro C; Brunetti L; Sportoletti P; Tiacci E; Di Raimondo F; Falini B
    Blood; 2015 May; 125(22):3455-65. PubMed ID: 25795919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FlT3-ITD in acute myeloid leukemia with the NPM1-mutation.
    Zhu HH; Liu YR; Jiang H; Lu J; Qin YZ; Jiang Q; Bao L; Ruan GR; Jiang B; Huang X
    Leuk Res; 2013 Jun; 37(6):624-30. PubMed ID: 23473998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.
    Schnittger S; Kern W; Tschulik C; Weiss T; Dicker F; Falini B; Haferlach C; Haferlach T
    Blood; 2009 Sep; 114(11):2220-31. PubMed ID: 19587375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The surface molecular signature of leukemic cells is associated with NPM1 mutations and FLT3 -ITD in patients with de novo acute myeloid leukemia.
    Su L; Gao SJ; Li W; Tan YH; Cui JW; Han W
    Acta Haematol; 2014; 131(3):148-52. PubMed ID: 24192815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34 expression and the outcome of nucleophosmin 1-mutated acute myeloid leukemia.
    Juncà J; Garcia O; Garcia-Caro M; Vila J; Zamora L; Cabezón M; Alonso E; de la Banda E; Rodríguez-Hernández I; Ribera JM; Millá F
    Ann Hematol; 2016 Dec; 95(12):1949-1954. PubMed ID: 27595757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone Marrow Clonogenic Myeloid Progenitors from
    Guardia RD; González-Silva L; López-Millán B; Rodríguez-Sevilla JJ; Baroni ML; Bueno C; Anguita E; Vives S; Palomo L; Lapillonne H; Varela I; Menendez P
    Genes (Basel); 2020 Jan; 11(1):. PubMed ID: 31936647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.